Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01639729 · ClinicalTrials.gov registry record · Phase 1
Effect of Delivery Route on PK of Sufentanil NanoTab
A Phase 1 study of Pharmacokinetics, sponsored by Talphera.
- Completed
- Registry status
- Phase 1
- Development phase
- 25
- Enrollment target
- 1
- Study location
NCT01639729: Completed Phase 1 study of Pharmacokinetics, sponsored by Talphera.
NCT01639729 is a Phase 1 study of Pharmacokinetics that has completed, run by Talphera. The registered enrollment target is 25 participants, below the 61-participant average among 37 other Pharmacokinetics trials with a reported enrollment target (59% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01639729, a Phase 1 study of Pharmacokinetics, has completed, sponsored by Talphera.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 25 participants
- Enrollment target
- 1
- Study location
Study Summary
Determine whether the amount of drug absorbed is different if the tablet is placed under the tongue, placed between the cheek and gum, or swallowed.
Primary Outcome
total amount of sufentanil absorbed
Conditions Studied
Interventions
- DRUG Treatment A: Sufentanil IV
- DRUG Treatment B: Sufentanil NanoTab Sublingual
- DRUG Treatment C: Sufentanil NanoTab Buccal
- DRUG Treatment D: Sufentanil NanoTab Oral
Study Locations (1)
Kansas
- PRA - Lenexa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2012-07 |
| Est. Completion | 2012-07 |
| Phase | Phase 1 |
What the finished NCT01639729 record still lists
NCT01639729 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 25 participants, a relatively small participant target, below the 61-participant average among 37 other Pharmacokinetics trials with a reported enrollment target (59% lower).
The record links to 1 condition, with Pharmacokinetics appearing as the primary indexed condition, and to 4 interventions - of which Treatment A: Sufentanil IV is the first listed.
NCT01639729 reports a single indexed study location in Kansas.
Frequently Asked Questions
What is clinical trial NCT01639729 about?
NCT01639729 is a clinical study titled "Effect of Delivery Route on PK of Sufentanil NanoTab". Determine whether the amount of drug absorbed is different if the tablet is placed under the tongue, placed between the cheek and gum, or swallowed.
What is the current status of trial NCT01639729?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 2012-07. Estimated completion is 2012-07.
What conditions does trial NCT01639729 study?
This clinical trial studies the following conditions: Pharmacokinetics.
What interventions are being tested in trial NCT01639729?
The interventions under investigation include: Treatment A: Sufentanil IV (DRUG), Treatment B: Sufentanil NanoTab Sublingual (DRUG), Treatment C: Sufentanil NanoTab Buccal (DRUG), Treatment D: Sufentanil NanoTab Oral (DRUG).
Who is sponsoring clinical trial NCT01639729?
This trial is sponsored by Talphera, which has 18 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01639729 being conducted?
This trial has 1 study location across Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pharmacokinetics
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01639729's enrollment target sits among peer trials
25 22nd of 37 higher than 16 of 37 other Pharmacokinetics trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pharmacokinetics trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Phase1/2a Study for IPG7236 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
High Potency Cannabis: Acute and Protracted Effects
RECRUITING · Phase 1
-
Comparing the Extent to Which Two Evolocumab Drug Products Are Made Available in the Body After a Single Subcutaneous Dose
RECRUITING · Phase 1
-
Single Dose Study, Pharmacokinetics of Oxycodone and PF614 Co-Administered With Nafamostat (PF614-MPAR-102)
RECRUITING · Phase 1
-
Safety and PK of Ceftibuten-ledaborbactam Etzadroxil Fixed-dose Combination
RECRUITING · Phase 1
-
A Study to Investigate Lithium Brain/Plasma Pharmacokinetics and Safety of an AL001 Oral Capsule Compared to a Marketed Immediate-release Lithium Carbonate Capsule in Healthy Adult Subjects
ACTIVE NOT RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01166854 · 25 participants
Characterization of Familial Myopathy and Paget Disease of Bone
- NCT01913106 · 25 participants · Phase 1
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
- NCT02138669 · 25 participants · NA
Intacs Prescription Inserts for Keratoconus Patients
- NCT02174549 · 25 participants · Phase 1
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia